Navigation Links
GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start.
Date:8/19/2007

PHILADELPHIA, Aug. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK), one of the world's largest vaccine manufacturers, today announced that HHS has placed another order to purchase bulk H5N1 antigen for the US national stockpile of pre-pandemic vaccines. The company also announced the start of the first North American pre-pandemic vaccine trials in the company's global pre-pandemic influenza program.

HHS Order

The company has received a second task order for 22.5 million doses of 15 mcg H5N1 bulk vaccine antigen from the U.S. Department of Health and Human Services (HHS) under a contract [HHS100200700027I] awarded in November 2007. This is in addition to the 5 million doses of H5N1 clade 2 bulk antigen at 15 mcg HA/dose ordered in November 2006. The additional task order procures an additional 9 million doses of H5N1 clade 2 bulk vaccine produced in the 2006 manufacturing campaign and 13.5 million doses of H5N1 clade 2 bulk vaccine expected to be produced in the 2007 manufacturing campaign.

Under the terms of the contract, GSK will manufacture the bulk vaccine product at the GSK manufacturing site in Ste. Foy, Canada and store bulk H5N1 antigen at the GSK site in Marietta, PA. Terms of the contract also state that GSK may be directed by HHS to formulate this bulk antigen at some point in the future. Additionally, HHS also has the option to purchase pre-pandemic vaccines together with one of GSK's proprietary adjuvant systems, which could mean that less antigen would be needed per dose to achieve a protective immune response. Funding for this contract is provided through the Office of Biomedical Advanced Research and Development Authority (BARDA) in the Assistant Secretary for Preparedness and Response (ASPR).

David Stout, President, Pharmaceutical Operations, GlaxoSmithKline said: "We applaud the US government's proactive steps in protecting American citizens against this potential public health threat. We are committed to helpi
'/>"/>

SOURCE GlaxoSmithKline

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
3. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
4. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
5. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
6. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
7. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
8. Researchers Discover Gene For Rare Skin Disorder
9. Remarks by President Bush on Stem Cell Veto and Executive Order
10. IMPAX Presents at Movement Disorder Societys 11th International Congress of Parkinsons Disease and Movement Disorders
11. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The House of Yahweh ... revealing to the whole world, including even the most devout ... in his new article. , Yisrayl says it all started ... by the Catholic Church. He says this plan included removing ... and replacing it with titles such as Lord and God. ...
(Date:7/25/2014)... 2014 iTanSmart is a patented iOS ... app provides a tailored approach to eliminating the guesswork ... and skin damage. In his review, Eaton had positive ... of iTanSmart. , Eaton begins his commentary ... ‘better organized’ and ‘great alternative’ to its related Android ...
(Date:7/25/2014)... According to the Addict Him To You Pdf review ... that teaches women how to get the love of the ... review that this book consists of 4 parts, including:, ... commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart deeply ...
(Date:7/25/2014)... As the category creator and world leader in healthy chocolate, ... and improve individual lives worldwide through its exclusive and healthy ... successful Austin, Texas based "Xocai Activ Drink" author, is scheduled ... to promote the up and coming mxicorp.com/company/igc Eric Worre engagement ... been a leader in the Network Marketing Profession for over ...
(Date:7/25/2014)... July 25, 2014 At World T.E.A.M. ... July 19, 17 participating developmentally-disabled teens and young adults ... if off-road bicycling, canoeing and hiking can be challenging. ... at the scenic Chesapeake and Ohio Canal National ... athletes both disabled and able-bodied. Under slightly overcast skies ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3
... Oregon Health & Science University Cancer Institute researchers have opened ... (CML). , We are looking under the surface of CML ... We have discovered abnormal cells in the early stem cell ... CML clone. These are abnormal cells that are not part ...
... federal court in Los Angeles has,opened the door ... firm,Johnson & Johnson, whose subsidiary McNeil Nutritionals has ... Splenda. United,States District Dale S. Fischer rejected Johnson ... charge that the plaintiffs had unreasonably,delayed bringing suit, ...
... of Bruce,Yarwood, President and CEO, American Health Care Association ... the entire long term care profession and the frail,elderly ... nation,s nursing,and assisted living facilities, I commend Hillary Clinton ... issue of long term,care in America. We know that ...
... December 8, 2007 -- Results from two investigational Phase ... provide preliminary anti-tumor activity in patients with relapsed and/or ... that 10 of 21 (48 percent) evaluable patients had ... bortezomib combination treatment. Data from a second study, ...
... Patient-Focused Organization Reaches Out to Educate Chicagoans, ... inform and empower the people of Chicago, SAVE ... 25-minute live,call-in show on the Chicago Access Network ... at 6:00 PM on CAN-TV, Channel 21., ...
... December 8, 2007 Researchers may be able to ... directly targeting novel molecules in the brain instead of ... longer times for medication to take effect, according to ... Neuropsychopharmacology (ACNP) annual meeting. The antidepressant is also thought ...
Cached Medicine News:Health News:OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia 2Health News:Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Health Care Knowledge Empowers the Public 2Health News:Study shows new strategy for developing antidepressants 2Health News:Study shows new strategy for developing antidepressants 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: